Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancerPatient recruitment ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced solid tumor regression data from Bantam's lead ...

With the clearance of an investigational new drug application from the FDA, a phase 1/2a study will evaluate VS-7375 in KRAS ...

Presentation will take place during the “Developmental Therapeutics - Immunotherapy” session on May 31, 2025, from 3:00 – 6:00pm CT at McCormick Place, ChicagoFORT LAUDERDALE, Fla. and WEST DES MOINES ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the ...

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

NovoCure Limited’s NVCR share price has surged by 7.54%, which has investors questioning if this is right time to sell.

K-TRACK™ ctDNA test from Gene Solutions predicts cancer relapse up to 19.5 months early with up to 96.3% accuracy, bringing ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.